RAC 2.92% $1.59 race oncology ltd

RAC - Charts & Price Action, page-12303

  1. 275 Posts.
    lightbulb Created with Sketch. 1050
    I suspect there will be multiple higher volume days that will help flush Bill Garner out more quickly than that timeline and also attract new investors to RACE.

    These could include:
    - First patient(s) treated in EMD AML trial in Aust;
    - National and possibly international media coverage of world first FTO trial (Stratum 2 EMD AML trial) based on Dr T comments on the other forum;
    - Zantrene IV formulation been incorporated into EMD AML trial (my speculation);
    - Melanoma in-vivo results including synergies with PD-1 inhibitors and associated patents;
    - Announcement on US IND for solid tumours and RACE to announce RACE 007 clinical trial, which could include possible pharma partners supplying their drug for free for the trial (speculation);

    These are all relatively near term potential catalysts and I believe BG's holdings will be absorbed much more quickly with the anticipated news flow than his historical rate of selling during a relatively quiet news period and downtrend in the Biotech sector.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.